The Canadian Adverse Drug Reaction Newsletter (CADRN) is published 4 times a year by Health Canada to alert health professionals to potential medication interactions, adverse drug reactions and concerns about therapeutic products. After the current issue of CADRN appears in this issue of CMAJ, it will be redesigned with a fresh, new look and printed separately from CMAJ, although it will still be delivered with the journal. This will make it easier for physicians to save this important document for future reference. CADRN will still be listed in CMAJ's index and table of contents. In addition, CMAJ's “Health and Drug Alerts” page, which is written by our editorial staff, will regularly (and briefly) explain what is new, important and should be done about serious or under-recognized adverse drug reactions. As well, physicians will be reminded regularly how to report adverse reactions to Health Canada. Drug alerts from Health Canada and the US Food and Drug Administration will continue to be featured regularly in eCMAJ (www.cma.ca/cmaj). We anticipate that these changes will help us deliver concise and relevant information to physicians, and ultimately will increase the reporting of postmarketing adverse events.
J
In this issue
Article tools
